What's breaking now, across thousands of outlets.
We haven't written up this one. Channel News Asia has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
The providers of Clairity Breast, a new FDA-approved AI tool, claim their tech provides an accurate five-year risk assessment for breast cancer, for just $249. Dr. Céline Gounder shares her thoughts.
The spread is widening between AI leaders OpenAI and Anthropic as a sell-off in CoreWeave leads neocloud stocks lower.
Key PointsASML plans to increase manufacturing capacity beyond its prior 30% target.
Some Pro features require payment, even if your phone came with the Pro plan.
